Epinastine
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Epinastine (DB00751): Toward Allergic Urticaria
One-Sentence Summary
Epinastine is a second-generation H1-antihistamine and mast cell stabilizer; the local regulatory record for its original approved indication is not available in this Evidence Pack (no NDA/license on file — drug is currently not marketed in this jurisdiction). The TxGNN model’s strongest supported prediction is Allergic Urticaria, backed by 2 post-marketing clinical studies and 10 relevant publications (including RCTs on H1-antihistamine wheal/flare suppression). A second, much weaker prediction — Rosacea Conjunctivitis — has no supporting trials or literature and is flagged Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license record on file); internationally marketed as Alesion® (Japan) for allergic rhinitis, eczema/dermatitis, urticaria and pruritus, per clinical-trial documentation in this pack |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.28% |
| Evidence Level | L2 |
| Market Status | Not Marketed (未上市, 0 licenses on file) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Formal DrugBank mechanism-of-action text is not available in this pack (data gap DG002). However, the literature evidence included here documents epinastine’s pharmacology directly: it is a potent H1-receptor antagonist that also suppresses antileukotriene, anti-PAF and antibradykinin pathways, and it inhibits mediator release from mast cells and eosinophils (PMID 12845334). This is the standard mechanistic basis for treating histamine-mediated urticaria — H1-receptor blockade plus mast cell stabilization directly targets the wheal-and-flare pathophysiology of allergic urticaria.
Epinastine is already marketed internationally (Alesion®, Japan) with a labeled indication covering urticaria among other atopic conditions, and two large Japanese post-marketing surveillance studies (combined N ≈ 5,800) specifically evaluated its real-world use in patients with urticaria and pruritus. Several controlled comparative studies (e.g., PMID 10442525, 29723372, 19558008) confirm epinastine’s histamine-wheal-suppressing potency alongside other approved second-generation antihistamines. This gives the TxGNN prediction a mechanistically direct and clinically corroborated basis, in contrast to the Rosacea Conjunctivitis prediction below, whose underlying pathophysiology (meibomian gland dysfunction, neurogenic inflammation, Demodex-related inflammation) is not primarily histamine-driven and is not supported by any trial or literature evidence in this pack.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02238223 | N/A (PMS) | Completed | 2,001 | Post-marketing surveillance of Alesion® (epinastine) tablets under real-world use, covering allergic rhinitis, asthma, eczema/dermatitis, urticaria, pruritus, prurigo and psoriasis vulgaris with itching |
| NCT02238236 | N/A (PMS) | Completed | 3,793 | Post-marketing drug-use survey of Alesion® Dry Syrup in Japanese paediatric patients with allergic rhinitis, eczema/dermatitis, urticaria and pruritus |
Both trials are observational post-marketing surveillance (real-world safety/use data), not randomized controlled efficacy trials — they establish safety and usage patterns in urticaria populations but are not direct efficacy comparators.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10442525 | 1999 | RCT | Allergy | Double-blind crossover study: epinastine among six H1-antihistamines suppressing histamine-induced wheal and flare for 24h vs. placebo |
| 29723372 | 2018 | RCT | An Bras Dermatol | Comparative suppression of histamine wheal/flare by major H1-antihistamines marketed in Brazil, relevant to urticaria/angioedema management |
| 19558008 | 2009 | RCT | Ann Allergy Asthma Immunol | Comparison of first- vs. second-generation antihistamines in suppressing histamine- and allergen-induced skin reactions relevant to mast cell-driven urticaria |
| 12845334 | 2000 | Review | Drugs of Today | Epinastine pharmacology update: H1-antihistaminic, antileukotriene, anti-PAF, antibradykinin activity; inhibits mast cell mediator release |
| 15510239 | 2004 | Review | Drugs of Today | Epinastine hydrochloride reviewed for atopic disease, including allergic conjunctivitis, eczema, rhinitis and urticaria symptom control |
| 11829715 | 2002 | Review | Expert Opin Investig Drugs | Antihistamines in late-phase development for allergic disease, including chronic idiopathic urticaria, driven by shared histamine-mediated mechanisms |
| 34387278 | 2021 | Review | Curr Opin Allergy Clin Immunol | Receptor-affinity profiling of ophthalmic/systemic antihistamine agents including epinastine |
| 10876807 | 2000 | Review | Nihon Yakurigaku Zasshi | Cetirizine pharmacology review citing epinastine as a comparator antihistamine for wheal-response suppression |
| 18597008 | 2008 | Cohort | Methods Find Exp Clin Pharmacol | Large-scale surveillance (n=1,742) of sedative profiles across H1-antihistamines including epinastine |
| 18524543 | 2008 | — | J Dermatol Sci | Regulatory effects of antihistamines on dendritic cell/T-cell responses relevant to urticaria and atopic dermatitis pathogenesis |
US Market Information
No NDA or marketing authorization is currently on file (0 licenses; market status: 未上市 / Not Marketed). Internationally, epinastine is marketed as Alesion® (Japan) in tablet and dry syrup formulations for allergic rhinitis, eczema/dermatitis, urticaria and pruritus, per the clinical trial records cited above.
Safety Considerations
Please refer to the package insert for safety information. (No key warnings, contraindications, or DDI data are currently on file for this drug — the local safety label has not yet been retrieved, which is a blocking data gap; see below.)
Conclusion and Next Steps
Decision: Proceed with Guardrails (Allergic Urticaria) — Hold (Rosacea Conjunctivitis)
Rationale:
- Allergic Urticaria has a mechanistically direct rationale (H1-antagonism/mast cell stabilization), international marketing precedent for urticaria, and L2-level evidence (post-marketing surveillance in ~5,800 patients plus supportive RCTs on antihistamine efficacy), but no local NDA and no drug-specific placebo-controlled urticaria RCT — hence guardrails rather than a clean Go.
- Rosacea Conjunctivitis has no clinical trial or literature support and a mechanistically weak rationale (non-histamine-driven pathophysiology) — Hold, not pursued further at this time.
To proceed, the following is needed:
- Local drug label / warnings & contraindications (DG001, blocking — required before any S1 safety evaluation can proceed)
- Confirmed DrugBank mechanism-of-action record (DG002)
- A randomized, placebo-controlled trial of epinastine specifically in allergic/chronic urticaria (current evidence is PMS + indirect comparator RCTs, not disease-specific RCTs)
- Regulatory pathway assessment, since the drug currently holds no marketing authorization in this jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.